Creation of Porous Fibers for Adsorbing Pathogenic Substances in Intractable Diseases
NQ Score
56/100
Key facts
- Creation of Porous Fibers for Adsorbing Pathogenic Substances in Intractable Diseases
- Toray Industries has developed a technology to control the pore size of PMMA porous fibers up to 1,000nm. This allows for the selective removal of large pathogenic substances like autoantibodies and exosomes, offering new blood purification treatment options.
- Source: article
- Date: Thu Mar 26 2026 22:54:46 GMT+0900 (Japan Standard Time)
Direct answer
Toray Industries has developed a technology to control the pore size of PMMA porous fibers up to 1,000nm. This allows for the selective removal of large pathogenic substances like autoantibodies and exosomes, offering new blood purification treatment options.
- Citation
- Creation of Porous Fibers for Adsorbing Pathogenic Substances in Intractable Diseases (Thu Mar 26 2026 22:54:46 GMT+0900 (Japan Standard Time)), article
- Source
- article
- Date
- Thu Mar 26 2026 22:54:46 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
Toray Industries has developed a technology to control the pore size of PMMA porous fibers up to 1,000nm. This allows for the selective removal of large pathogenic substances like autoantibodies and exosomes, offering new blood purification treatment options.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What is the key advantage of this technology?
- A: It allows for real-time control of PMMA porous fiber pore sizes up to approximately 1,000nm, which is 50 times larger than conventional capabilities, while maintaining structural strength.
- Q: What are the key facts in this article?
- A: Toray Industries has developed a technology to control the pore size of PMMA porous fibers up to 1,000nm. This allows for the selective removal of large pathogenic substances like autoantibodies and exosomes, offering new blood purification treatment options.
- Q: What is the direct answer?
- A: Toray Industries has developed a technology to control the pore size of PMMA porous fibers up to 1,000nm. This allows for the selective removal of large pathogenic substances like autoantibodies and exosomes, offering new blood purification treatment options.